Share ownership Shionogi & Co., Ltd.

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-06-08 EDT			5-day change	1st Jan Change
2,844.50 ^JPY	-0.72%		-0.72%	+0.12%

06-05	Shionogi & Co Ltd Announces New Product Launch of 'ENDEAVORRIDE'	CI
06-01	US regulator approves oral drug from Japan's Shionogi to prevent COVID-19	RE

Share class: Shionogi & Co., Ltd.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	889,632,195	807,962,031 ( 90.82 %)	38,656,758 ( 4.345 %)	90.82 %

Major shareholders: Shionogi & Co., Ltd.

Name	Equities	%	Valuation
Sumitomo Life Insurance Co. 6.274 %	55,812,000	6.274 %	1 129 M ¥
Wellington Management Co. LLP 3.681 %	32,746,984	3.681 %	662 M ¥
SHIONOGI & CO., LTD. 3.334 %	29,655,900	3.334 %	600 M ¥
BlackRock Fund Advisors 3.216 %	28,608,380	3.216 %	579 M ¥
Sumitomo Mitsui Banking Pension Fund 3.199 %	28,455,000	3.199 %	576 M ¥
Amova Asset Management Co., Ltd. 2.893 %	25,732,700	2.893 %	521 M ¥
Nippon Life Insurance Co. 2.836 %	25,227,000	2.836 %	510 M ¥
PING AN INSURANCE (GROUP) COMPANY OF CHINA, LTD. 2.143 %	19,068,000	2.143 %	386 M ¥
BlackRock Japan Co. Ltd. 1.882 %	16,746,700	1.882 %	339 M ¥
SUMITOMO MITSUI FINANCIAL GROUP, INC. 1.085 %	9,651,000	1.085 %	195 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
RhumbLine Advisers LP 0.004734 %	84,231	0.004734 %	851 997 ¥
Sterling Capital Management LLC 0.003305 %	58,807	0.003305 %	594 833 ¥
Hourglass Capital LLC 0.002861 %	50,900	0.002861 %	514 854 ¥
GAMMA Investing LLC 0.000928 %	16,520	0.000928 %	167 100 ¥
PNC Wealth Management LLC 0.000701 %	12,471	0.000701 %	126 144 ¥
Old National Bank (Investment Management) 0.000672 %	11,962	0.000672 %	120 996 ¥
Salomon & Ludwin LLC 0.000143 %	2,550	0.000143 %	25 793 ¥
Ancora Private Wealth Advisors LLC 0.000083 %	1,477	0.000083 %	14 940 ¥
Westside Investment Management LLC 0.000059 %	1,054	0.000059 %	10 661 ¥

Breakdown by shareholder type

Institutional	18.54%
Others	9.59%
Shionogi & Co., Ltd.	3.33%
Ping An Insurance (Group) Co. of China Ltd.	2.14%
Sumitomo Mitsui Financial Group, Inc.	1.08%
Suzuken Co., Ltd.	0.43%
Kissei Pharmaceutical Co., Ltd.	0.36%
MS&AD Insurance Group Holdings, Inc.	0.35%
Sompo Holdings, Inc.	0.34%
Kaneka Corp.	0.23%
Toho Holdings Co., Ltd.	0.18%
Tokio Marine Holdings, Inc.	0.17%
Nagase & Co., Ltd.	0.15%
Medipal Holdings Corp.	0.11%
HOKUYAKU TAKEYAMA Holdings, Inc.	0.09%
Okayama Paper Industries Co., Ltd.	0.07%
Senshu Ikeda Holdings, Inc.	0.04%
RAIZNEXT Corp.	0.01%
Ain Holdings, Inc.	0.01%
Okayamaken Freight Transportation Co., Ltd.	0.01%
Unknown	62.77%

Based on 1000 largest holdings

Geographical origin of shareholders

Japan	25.15%
United States	7.1%
China	2.14%
United Kingdom	0.57%
Hong Kong	0.47%
Germany	0.44%
Netherlands	0.31%
Sweden	0.24%
Canada	0.16%
Australia	0.15%
Ireland	0.13%
New Zealand	0.1%
Finland	0.06%
Switzerland	0.06%
Belgium	0.02%
Spain	0.02%
Denmark	0.02%
Singapore	0.01%
Liechtenstein	0.01%
Luxembourg	0.01%
Norway	0.01%
Italy	0.01%
Austria	0.01%
South Africa	0.01%

Based on 1000 largest holdings

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

Employees

4,955

Sector

Pharmaceuticals

Calendar

Earnings release - Q1 2027

More about the company